Lozano I, Rondan J, Vegas JM
www.jacc.org/doi/abs/10.1016/j.jcin.2023.11.042
Summary
This Letter to the Editor comments on the TRANSFORM I randomized trial comparing sirolimus-coated and paclitaxel-coated balloons in de novo small coronary vessels. The authors discuss the study’s findings, highlighting the superior angiographic outcomes observed with paclitaxel-coated balloons and questioning the concept of a class effect among drug-coated balloons. The letter places these results in the broader context of drug-coated balloon development, clinical adoption, and ongoing debates regarding paclitaxel versus sirolimus technologies in coronary interventions.
